Drug Profile
Research programme: anticancer antibodies - VBL Therapeutics
Alternative Names: VB 600 seriesLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator VBL Therapeutics
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer